305 related articles for article (PubMed ID: 27756245)
1. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.
Kawaguchi M; Hara N; Bilim V; Koike H; Suzuki M; Kim TS; Gao N; Dong Y; Zhang S; Fujinawa Y; Yamamoto O; Ito H; Tomita Y; Naruse Y; Sakamaki A; Ishii Y; Tsuneyama K; Inoue M; Itoh J; Yasuda M; Sakata N; Jung CG; Kanazawa S; Akatsu H; Minato H; Nojima T; Asai K; Miura Y
BMC Cancer; 2016 Oct; 16(1):805. PubMed ID: 27756245
[TBL] [Abstract][Full Text] [Related]
2. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
[TBL] [Abstract][Full Text] [Related]
3. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
[TBL] [Abstract][Full Text] [Related]
4. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor, AT motif binding factor 1 (ATBF1), translocates to the nucleus with runt domain transcription factor 3 (RUNX3) in response to TGF-beta signal transduction.
Mabuchi M; Kataoka H; Miura Y; Kim TS; Kawaguchi M; Ebi M; Tanaka M; Mori Y; Kubota E; Mizushima T; Shimura T; Mizoshita T; Tanida S; Kamiya T; Asai K; Joh T
Biochem Biophys Res Commun; 2010 Jul; 398(2):321-5. PubMed ID: 20599712
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
7. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
Liu B; Miyake H; Nishikawa M; Fujisawa M
Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.
Chang CC; Tai CJ; Su TC; Shen KH; Lin SH; Yeh CM; Yeh KT; Lin YM; Jiang MC
Ann Diagn Pathol; 2012 Oct; 16(5):362-8. PubMed ID: 22476051
[TBL] [Abstract][Full Text] [Related]
10. Expression and subcellular localization of AT motif binding factor 1 in colon tumours.
Kataoka H; Miura Y; Kawaguchi M; Suzuki S; Okamoto Y; Ozeki K; Shimura T; Mizoshita T; Kubota E; Tanida S; Takahashi S; Asai K; Joh T
Mol Med Rep; 2017 Sep; 16(3):3095-3102. PubMed ID: 28713972
[TBL] [Abstract][Full Text] [Related]
11. Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.
Tsai YS; Jou YC; Tung CL; Lin CT; Shen CH; Chen SY; Tsai HT; Lai CL; Wu CL; Tzai TS
Virchows Arch; 2014 Jun; 464(6):717-24. PubMed ID: 24733561
[TBL] [Abstract][Full Text] [Related]
12. Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients.
Che X; Yang D; Zong H; Wang J; Li X; Chen F; Chen X; Song X
Urol Oncol; 2012; 30(4):450-6. PubMed ID: 21795072
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 expression in urothelial carcinoma of the bladder.
Suren D; Yildirim HT; Atalay I; Sayiner A; Yildirim M; Alikanoglu AS; Sezer C
J BUON; 2018; 23(6):1882-1886. PubMed ID: 30610817
[TBL] [Abstract][Full Text] [Related]
16. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
17. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
18. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma.
Adam RM; Danciu T; McLellan DL; Borer JG; Lin J; Zurakowski D; Weinstein MH; Rajjayabun PH; Mellon JK; Freeman MR
Cancer Res; 2003 Jan; 63(2):484-90. PubMed ID: 12543806
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of p53 Expression Intensity in Urothelial Cancers.
Qamar S; Inam QA; Ashraf S; Khan MS; Khokhar MA; Awan N
J Coll Physicians Surg Pak; 2017 Apr; 27(4):232-236. PubMed ID: 28492153
[TBL] [Abstract][Full Text] [Related]
20. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
